3 Firms Build $462M Sale Of Paratek Pharmaceuticals
Commercial-stage biopharmaceutical company Paratek Pharmaceuticals Inc. said Tuesday that it will become a private company after agreeing to a purchase by Gurnet Point Capital and Novo Holdings A/S in a deal...To view the full article, register now.
Already a subscriber? Click here to view full article